GlassScriptPhysician profile
Maureen Cooper
NPI 1356310890
$84,976.79
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $5,765 · 2021: $13K · 2022: $12K · 2023: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,900 · Travel and Lodging: $4,959 · Food and Beverage: $267 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,900.00 |
| Travel and Lodging | $4,958.70 |
| Food and Beverage | $266.79 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $65,861.91 | 2019-2023 | Nplate |
| Janssen Biotech, INC. | $5,033.37 | 2019-2022 | |
| Incyte Corporation | $4,638.21 | 2020-2021 | |
| Glaxosmithkline, LLC. | $2,389.74 | 2020-2022 | |
| Array Biopharma INC | $1,901.57 | 2021 | |
| Novartis Pharmaceuticals Corporation | $1,779.45 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $1,531.97 | 2021-2022 | |
| Genentech USA, INC. | $998.74 | 2019-2020 | |
| Daiichi Sankyo INC. | $159.68 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $102.67 | 2022 | |
| Seagen INC. | $61.54 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $60.45 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.12 | 2021-2022 | |
| Gilead Sciences, INC. | $44.99 | 2021-2022 | |
| Macrogenics, INC. | $39.71 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $31.08 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $27.70 | 2021 | |
| Pfizer INC. | $25.90 | 2019-2021 | |
| The Binding Site INC. | $25.00 | 2020 | |
| Karyopharm Therapeutics INC. | $24.74 | 2021 | |
| Taiho Oncology, INC. | $23.57 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $21.57 | 2019 | |
| Celgene Corporation | $21.24 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $19.91 | 2021 | |
| Tersera Therapeutics LLC | $19.88 | 2022 | |
| Organon LLC | $18.61 | 2021 | |
| G1 Therapeutics, INC. | $18.34 | 2022 | |
| Puma Biotechnology, INC. | $18.09 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.17 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.